SAB Biotherapeutics Initiates IND-Enabling GLP Toxicology Study for SAB-142, Novel Immunotherapeutic for Type 1 Diabetes

November 21, 2022

https://www.globenewswire.com/news-release/2022/11/21/2559862/0/en/SAB-Biotherapeutics-Initiates-IND-Enabling-GLP-Toxicology-Study-for-SAB-142-Novel-Immunotherapeutic-for-Type-1-Diabetes.html

SIOUX FALLS, S.D., Nov. 21, 2022 (GLOBE NEWSWIRE) — SAB Biotherapeutics (Nasdaq:SABS), (“SAB”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies without the need for human donors, today announced SAB-142 is being progressed as a therapeutic agent to prevent and/or delay onset and progression of Type 1 diabetes (T1D) and potentially other T-cell mediated autoimmune diseases. In an IND-enabling GLP study, SAB-142 will be compared to an FDA-approved T-cell depleting therapeutic, to assess toxicity and pharmacodynamic effects.

Read more at globenewswire.com

Related news for (SABS)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.